Do You Need a License to Sell Peptides in Montana?

There is no standalone "peptide license" issued in Montana, so the useful answer depends entirely on what you are actually doing. Registering a business and reselling research-use-only compounds to other businesses, operating as a drug distributor, and running a licensed clinical practice are three distinct regulatory positions with three different answers — and most operators confuse them. Nearly every Montana business needs the ordinary commercial registration any business needs; whether anything sits on top of that depends on the nature of the product, the claims attached to it, and the channel it moves through. This article is informational and is not legal advice. The specifics belong to a Montana attorney and, where a licensed profession is involved, the board that regulates it.

Three questions hiding inside one

When an operator asks whether they need a license, they are usually asking three questions at once without separating them.

The first is the entity question. Any business selling goods generally needs to exist as a registered entity, hold the tax accounts appropriate to its activity, and file whatever the state and its municipality require of commercial sellers. This layer has nothing to do with peptides specifically. It is the same paperwork a bookstore or a supplement shop deals with, and your accountant or business attorney handles it as routine.

The second is the product-classification question, and this is where the real work sits. Research-use-only materials, dietary supplements, cosmetics, and prescription drugs are treated very differently, and the category a product falls into is not determined by what a supplier calls it. It is determined by how the product is labeled, how it is marketed, and what it is intended for. That last word does a lot of heavy lifting. A compound sold and labeled strictly for laboratory research occupies a different position than the same compound marketed with human-use language attached — and the question of where that line falls is one your counsel should answer for your specific business model, not one a supplier can answer for you.

The third is the channel question. Distributing drugs, wholesaling them, or dispensing them to individuals typically triggers authorization requirements administered at the state level, often through a board of pharmacy or an equivalent agency, sometimes with federal registration layered on top depending on the product. Whether your activity falls inside or outside that framework is a legal determination. Do not assume you are outside it because your supplier's website says "research use only," and do not assume you are inside it because the word peptide is involved. Ask directly, in writing, and get the answer from someone licensed to give it.

Which lane you are actually in

The fastest way to make progress is to stop asking "do I need a license" and start asking "which question does my specific activity raise, and who is qualified to answer it."

Nothing in that table is a conclusion about Montana law. It is a map of the questions to bring to people who can answer them for your facts. Two businesses in the same town, buying the same catalog, can land in different places depending on how they operate.

What research use only actually constrains

Research-use-only is not a disclaimer that makes obligations disappear. It is a description of what the material is supplied for, and it carries real constraints on both sides of the transaction.

On the supplier side, it means compounds are produced, tested, labeled, and sold for laboratory research. They are not FDA-approved drugs, they are not sold for human consumption, and no dosing, administration, or protocol guidance accompanies them. Real Peptides supplies on exactly these terms, without exception, to every account regardless of size.

On the buyer side, the constraint travels with the product. A wholesale account does not authorize anything beyond purchase and resale within the research channel, and it does not confer any professional or clinical permission. If your intended business model involves anything other than stocking and reselling research materials to other businesses, that model needs its own legal review — the supply relationship is not a substitute for it.

This matters commercially, not just legally. Buyers who understand the research-use lane build catalogs, marketing, and customer communications that stay inside it. Buyers who blur the line create exposure that no supplier can absorb on their behalf. Where the compound science is genuinely interesting — and it often is — research suggests certain peptides warrant continued laboratory investigation, and studies indicate mechanisms worth exploring. That is the honest register. It is not a promise, and it should not appear in your customer-facing copy as one.

Questions worth putting to counsel before the first order

A short, well-aimed consultation costs far less than an unwound business model. Bring these questions, phrased for your actual operation:

What is my product classification given how I intend to label and market it, and what changes that classification? Does my customer type — other businesses, research institutions, or something else — affect the answer? Does anything in my activity constitute distribution, wholesaling, or dispensing as Montana defines those terms? If licensed professionals are involved in my business, what does their board permit and prohibit? What records am I expected to keep about what I purchased, from whom, and where it went? And what marketing language would move me from one regulatory category into another?

That last question is the one most operators underestimate. Claims are not decoration. A single line of website copy promising an outcome can change how a regulator characterizes an entire catalog. Have counsel review your storefront copy, not only your entity paperwork.

Also ask what documentation you should require from any supplier before you buy, because the answer usually shapes your purchasing decision more than anything else on the list.

Why supplier documentation becomes your documentation

Whatever your legal position turns out to be, it rests partly on what you can prove about the material you stock. If you cannot show what a compound is, what batch it came from, and what testing was performed on it, you are relying on a supplier's word — and your customers are relying on yours.

This is where wholesale programs separate sharply. Some suppliers publish certificates of analysis openly, batch by batch, so any buyer can check the result before ordering. Others treat testing data as a paid add-on, release it only after a purchase, or provide a document with no traceable batch identifier — which makes it decorative rather than verifiable. Some show a single historical analysis and imply it represents current production. A COA that cannot be tied to the specific lot in your inventory does not do the job you need it to do.

Pricing opacity is the second common pattern. Programs that hide tiers behind a sales call, quote different numbers to different buyers, or attach fees that only appear at checkout make it impossible to model your own costs before committing. That is a reason to ask more questions, not fewer.

The third is fulfillment ambiguity. Where does the product ship from, who handles it, and what happens if a batch arrives compromised? A supplier who cannot answer plainly is asking you to absorb their risk. None of these are exotic demands. They are the baseline a serious buyer applies to any supplier in any regulated adjacent category, and the same standard applies whether you are stocking a handful of compounds or building out a full catalog from a broad collection of popular peptides.

What Real Peptides does differently

Real Peptides publishes what most suppliers keep behind a login. Compounds are produced to 99%+ HPLC purity, and every batch goes through multi-panel testing before release rather than periodic spot checks on selected lots. The resulting certificates of analysis are publicly verifiable — a prospective buyer can look up the lab results for a listed compound, such as BPC-157, and read them before making any commitment or speaking to anyone. That ordering matters: verification comes first, the relationship second.

Fulfillment is US-based, with orders shipping in five to seven days, which means a Montana buyer receives product on the same terms as a buyer anywhere else in the country. Real Peptides does not maintain a facility or staff in Montana; it ships nationally from the United States.

The Wholesale Partner Program uses a three-step application: submit the application with your business details, receive review and verification of the business, then get account approval with access to wholesale pricing. Tiers are presented plainly rather than negotiated in the dark, and testing documentation is included with the product rather than sold alongside it.

What Real Peptides does not do is equally clear. It does not supply compounds for human use, does not provide dosing or administration guidance, and does not offer any opinion on whether your specific business model is permitted in your state. That determination is yours and your attorney's, and any supplier who tells you otherwise is selling you something other than peptides.

Moving from a legal question to a qualified account

If you have worked through classification, channel, and claims with counsel and concluded that stocking research-use-only compounds fits your business, the next step is qualification. Applications are reviewed for legitimate business status, and approved accounts get transparent tier pricing with verifiable testing attached to every batch. Get the legal answer first; the account follows from it, not the other way around.

For program details, see the wholesale peptides program overview, read the broader breakdown of do you need a license to sell peptides, or apply for a wholesale account when your business is ready to be reviewed.